ArticleCureus2026
DNA Vaccination Against Macrophage Migration Inhibitory Factor Protecting Mice From Experimental Pancreatitis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Macrophage migration inhibitory factor (MIF) has a pivotal role in the development of gastroenterological diseases, including pancreatitis. In this study, we aimed to explore the effect of deoxyribonucleic acid (DNA) vaccination producing an auto-MIF antibody on experimental pancreatitis and to provide additional evidence that MIF affects the development of pancreatitis. Methods Mice were treated with an MIF-DNA vaccine by introducing oligonucleotides encoding a helper T epitope into the cDNA sequence of murine MIF by in vivo electroporation. Thereafter, experimental pancreatitis was induced by seven repeated intraperitoneal injections of cerulein (50 μg/kg). Histological findings were evaluated in the pancreas. The levels of MIF, monocyte chemoattractant protein-1 (MCP-1), IL-1β, and heat shock protein 70 (HSP70) were analyzed with enzyme-linked immunosorbent assay (ELISA). Results The titer of MIF antibody was increased in the serum of mice 8 weeks after the treatment with MIF-DNA vaccine. In cerulein-induced pancreatitis, the histological findings in the pancreas were ameliorated in MIF-DNA vaccinated mice. The serum levels of MIF were lower in MIF-DNA vaccinated mice than those in mock-treated mice with pancreatitis. The increases in the serum and pancreatic levels of IL-1β and the serum level of MCP-1 were suppressed in MIF-DNA-vaccinated mice given cerulein. Furthermore, the pancreatic HSP70 level was upregulated in MIF-DNA-vaccinated mice given cerulein. Conclusion MIF-DNA vaccination protected mice from cerulein-induced pancreatitis via anti-inflammatory and cytoprotective effects. MIF-DNA vaccination may be an additional option for the treatment of pancreatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.